XENE Logo

Xenon Pharmaceuticals Inc. (XENE) 

NASDAQ$35.17-0.43 (-1.21%)
Market Cap
$2.72B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
916 of 924
Rank in Industry
524 of 527

XENE Insider Trading Activity

XENE Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$3,185,8555100

Related Transactions

PATOU GARYdirector0$01$200,947$-200,947
AULIN SHERRYChief Financial Officer0$01$770,912$-770,912
MORTIMER IANPRESIDENT & CEO0$03$2.21M$-2.21M

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise â€¦

Insider Activity of Xenon Pharmaceuticals Inc.

Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $3.19M worth of Xenon Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $4.57M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.

List of Insider Buy and Sell Transactions, Xenon Pharmaceuticals Inc.

2025-01-27SaleMORTIMER IANPRESIDENT & CEO
16,315
0.0216%
$40.50$660,806-3.58%
2025-01-24SaleMORTIMER IANPRESIDENT & CEO
22,468
0.0298%
$40.20$903,214-3.13%
2025-01-23SaleMORTIMER IANPRESIDENT & CEO
16,217
0.0213%
$40.08$649,977-3.11%
2024-12-18SaleAULIN SHERRYChief Financial Officer
18,709
0.0256%
$41.21$770,912-1.03%
2024-11-22SalePATOU GARYdirector
4,891
0.0064%
$41.09$200,947-4.13%
2024-03-08SaleGAROFALO ELIZABETH A.director
2,092
0.0027%
$45.69$95,583-13.08%
2024-03-07SaleROBIN SHERRINGTONEVP, Strategy & Innovation
7,137
0.0095%
$46.28$330,290-12.81%
2024-03-07SaleGANNON STEVENdirector
13,000
0.0173%
$46.28$601,615-12.81%
2023-12-14SalePATOU GARYdirector
7,598
0.0103%
$41.05$311,898+1.21%
2023-12-13SalePATOU GARYdirector
18,978
0.0257%
$39.99$758,983+4.60%
2023-08-24SaleSvoronos Dawndirector
25,000
0.0391%
$38.70$967,500+4.70%
2023-06-01SalePIMSTONE SIMON N.director
31,713
0.0485%
$38.82$1.23M+2.56%
2023-05-31SalePIMSTONE SIMON N.director
62,526
0.0956%
$38.70$2.42M+2.70%
2023-05-30SalePIMSTONE SIMON N.director
37,006
0.0576%
$39.28$1.45M+3.13%
2023-05-24SaleMORTIMER IANPRESIDENT & CEO
31,655
0.0482%
$41.41$1.31M-4.09%
2023-03-24SaleKENNEY CHRISTOPHER JOHNChief Medical Officer
700
0.0011%
$35.01$24,507+10.88%
2023-03-07SalePIMSTONE SIMON N.director
19,232
0.03%
$36.98$711,199+6.76%
2022-11-25SalePATOU GARYdirector
1,937
0.0032%
$34.79$67,390+8.14%
2022-09-02SaleAULIN SHERRYChief Financial Officer
15,355
0.0238%
$39.57$607,597-3.33%
2022-08-31SaleROBIN SHERRINGTONEVP, Strategy & Innovation
8,776
0.0134%
$38.80$340,509-2.86%
Total: 75
*Gray background shows transactions not older than one year

Insider Historical Profitability

26.38%
MORTIMER IANPRESIDENT & CEO
31302
0.0409%
$1.11M24+28.18%
PATOU GARYdirector
23573
0.0308%
$839,198.8024+22.11%
BVF PARTNERS L P/IL10 percent owner
1674468
2.1876%
$59.61M100<0.0001%
Hayden Michael Rdirector
161187
0.2106%
$5.74M10+44.6%
AZAB MOHAMMADdirector
57561
0.0752%
$2.05M51+72.32%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$193,151,375
134
8.18%
$2.8B
$11,588,217
69
42.07%
$2.65B
$1,376,668
53
18.46%
$2.38B
$1,275,975,557
32
19.44%
$2.87B
Xenon Pharmaceuticals Inc.
(XENE)
$5,066,938
27
26.38%
$2.72B

XENE Institutional Investors: Active Positions

Increased Positions97+42.73%6M+8.44%
Decreased Positions90-39.65%4M-5.74%
New Positions30New2MNew
Sold Out Positions21Sold Out623,017Sold Out
Total Postitions234+3.08%77M+2.7%

XENE Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$265,793.009.77%7.53M+607,606+8.78%2024-12-31
Avoro Capital Advisors Llc$200,147.007.36%5.67M00%2024-12-31
Driehaus Capital Management Llc$159,667.005.87%4.52M-75,126-1.64%2024-12-31
Wellington Management Group Llp$133,425.004.91%3.78M-65,836-1.71%2024-12-31
Braidwell Lp$102,921.003.78%2.91M+206,709+7.63%2024-12-31
Janus Henderson Group Plc$101,254.003.72%2.87M+314,363+12.32%2024-12-31
Commodore Capital Lp$96,777.003.56%2.74M+40,000+1.48%2024-12-31
Polar Capital Holdings Plc$95,281.003.5%2.7M+253,012+10.35%2024-12-31
Capital International Investors$89,967.003.31%2.55M-33,962-1.32%2024-12-31
Capital World Investors$81,043.002.98%2.29M-387,000-14.43%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.